Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine transporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cognitive Dysfunction; Hypotension, Orthostatic; Low Back Pain; Melanoma; Psychotic Disorders; Sleep Apnea Syndromes; Sleep Initiation and Maintenance Disorders; Tinnitus; Tobacco Use Disorder; Alcoholism; Amphetamine-Related Disorders; Deglutition Disorders; Depressive Disorder; Opioid-Related Disorders; Ovarian Neoplasms; Parkinson Disease; Schizophrenia; Stress Disorders, Post-Traumatic; Substance-Related Disorders; Alzheimer Disease; Brain Neoplasms; Cocaine-Related Disorders; Depressive Disorder, Major; Fatigue; Multiple Sclerosis; Narcolepsy; Postpoliomyelitis Syndrome; Sarcoma, Ewing; Sleep Apnea, Obstructive; Sleep Wake Disorders; Stroke; Attention Deficit Disorder with Hyperactivity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acute Coronary Syndrome; Child Development Disorders, Pervasive; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Irritable Bowel Syndrome; Opioid-Related Disorders; Panic Disorder; Parkinson Disease; Anxiety; Dementia; Depressive Disorder, Major; Obsessive-Compulsive Disorder; Psychomotor Agitation; Schizophrenia; Stroke; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acquired Immunodeficiency Syndrome; Acute Coronary Syndrome; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Anemia; Arthritis, Rheumatoid; Asthma; Carcinoma, Renal Cell; Cardiotoxicity; Constipation; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dyspepsia; Epilepsy; Erectile Dysfunction; Fibromyalgia; HIV Infections; Heart Failure; Hepatitis C; Hypertension; Hypoglycemia; Hypotension, Orthostatic; Immune System Diseases; Lice Infestations; Lipid Metabolism Disorders; Lung Diseases; Lupus Erythematosus, Systemic; Lymphoma; Malaria, Vivax; Nausea; Pain; Phenylketonurias; Premature Birth; Psychotic Disorders; Respiratory Tract Infections; Restless Legs Syndrome; Schizophrenia; Cholangitis; Meningitis; Muscle Spasticity; Neoplasms; Parkinson Disease; Tuberculosis, Multidrug-Resistant; Abscess; Acanthamoeba Keratitis; Breast Neoplasms; Bronchitis, Chronic; Cataract; Cellulitis; Cholecystitis, Acute; Conjunctivitis, Bacterial; Endophthalmitis; Infections; Inflammation; Influenza, Human; Otitis Externa; Otitis Media; Pelvic Inflammatory Disease; Pneumonia; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Severe Acute Respiratory Syndrome; Sinusitis; Skin Diseases; Tuberculosis; Tuberculosis, Pulmonary; Bacterial Infections; Eye Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Synaptic vesicle glycoprotein 2A modulator
ROUTE OF ADMINISTRATION: INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Aphasia; Canavan Disease; Essential Tremor; Stroke; Alzheimer Disease; Anemia, Sickle Cell; Bipolar Disorder; Brain Neoplasms; Cocaine-Related Disorders; Cognitive Dysfunction; Dyskinesia, Drug-Induced; Epilepsy, Absence; Epilepsy, Reflex; Glioblastoma; Glioma; Leukemia, Myeloid, Acute; Neuralgia, Postherpetic; Neuroblastoma; Obsessive-Compulsive Disorder; Opioid-Related Disorders; Parkinson Disease; Polyneuropathies; Psychotic Disorders; Restless Legs Syndrome; Stress Disorders, Post-Traumatic; Torticollis; Alcoholism; Anxiety; Dementia; Depressive Disorder; Epilepsies, Partial; Movement Disorders; Panic Disorder; Schizophrenia; Status Epilepticus; Subarachnoid Hemorrhage; Substance Withdrawal Syndrome; Epilepsy; Epilepsy, Tonic-Clonic; Seizures
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Obesity; Renal Insufficiency, Chronic; Infections; Influenza in Birds; Thrombocytopenia; Influenza, Human; Pneumonia; Purpura, Thrombocytopenic, Idiopathic; Severe Acute Respiratory Syndrome; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: EYE; OTHER
THERAPEUTIC INDICATION: Chronic Pain; Conjunctivitis, Allergic; Dermatitis; Dermatitis, Atopic; Fractures, Bone; Rhinitis, Allergic, Perennial
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Abdominal Pain; Cleft Palate; Postoperative Complications; Back Pain; Neoplasms; Pain; Pregnancy
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY
THERAPEUTIC INDICATION: Dementia; HIV Infections; Amyotrophic Lateral Sclerosis; Friedreich Ataxia; Parkinson Disease; Stroke; beta-Thalassemia; Acute Kidney Injury; Hemochromatosis; Pantothenate Kinase-Associated Neurodegeneration; Anemia, Sickle Cell; Thalassemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Neuraminidase inhibitor
ROUTE OF ADMINISTRATION: INHALATION
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 2; Infections; Influenza, Human; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Anxiety; Dementia; Depressive Disorder; Schizophrenia; Sleep Initiation and Maintenance Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: INTRAVENOUS; ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER
THERAPEUTIC INDICATION: Cytomegalovirus Infections; Ependymoma; Fallopian Tube Neoplasms; Meningitis, Aseptic; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Wilms Tumor; Biliary Tract Neoplasms; Brain Diseases; Brain Stem Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Neuroendocrine; Colorectal Neoplasms; Ganglioneuroblastoma; Gastrointestinal Stromal Tumors; Glioma; Hematologic Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Medulloblastoma; Myelodysplastic Syndromes; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Neurofibromatosis 1; Ovarian Neoplasms; Pancreatic Neoplasms; Pinealoma; Pituitary Neoplasms; Rectal Neoplasms; Retinoblastoma; Rhabdomyosarcoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Sarcoma; Skin Neoplasms; Small Cell Lung Carcinoma; Spinal Cord Neoplasms; Astrocytoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Choroid Plexus Neoplasms; Diffuse Intrinsic Pontine Glioma; Gliosarcoma; Melanoma; Neoplasm Metastasis; Neuroendocrine Tumors; Oligodendroglioma; Optic Nerve Glioma; Sarcoma, Ewing; Glioblastoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA gyrase inhibitor
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: EYE; OTHER
THERAPEUTIC INDICATION: Cataract; Tuberculosis; Bacterial Infections; Conjunctivitis, Bacterial; Eye Infections; Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Retinoid X receptor agonist
ROUTE OF ADMINISTRATION: ORAL; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Carcinoma, Intraductal, Noninfiltrating; Multiple Myeloma; Pituitary ACTH Hypersecretion; Alopecia Areata; Alzheimer Disease; Breast Neoplasms; Leukemia; Leukemia, Myeloid, Acute; Lung Neoplasms; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Parapsoriasis; Psoriasis; Sezary Syndrome; Carcinoma, Non-Small-Cell Lung; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Mycosis Fungoides; Psychotic Disorders; Schizophrenia; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Retinoid receptor agonist
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM
THERAPEUTIC INDICATION: Breast Neoplasms; Lichen Planus; Lupus Erythematosus, Cutaneous; Psoriasis; Hand Dermatoses; Eczema; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Hodgkin Disease; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sepsis; Small Cell Lung Carcinoma; Testicular Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Inflammatory Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Sarcoma; Stomach Neoplasms; Thrombosis; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: FK506-binding protein 1A inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER; UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Acute Lung Injury; Adenocarcinoma of Lung; Alcoholism; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Diabetic Retinopathy; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Frontotemporal Dementia; Gangliosidoses; Gaucher Disease; Glioblastoma; Glycogen Storage Disease Type II; Granulomatous Disease, Chronic; HIV Infections; Heart Failure; Hematologic Neoplasms; Hypercholesterolemia; Hyperinsulinism; Hypertension, Pulmonary; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Plasma Cell; Lung Neoplasms; Multiple Sclerosis, Relapsing-Remitting; Neurilemmoma; Parkinson Disease; Port-Wine Stain; Prostatic Neoplasms; Rectal Neoplasms; Respiratory Distress Syndrome; Sarcopenia; Scleritis; Small Cell Lung Carcinoma; Thalassemia; Uveitis, Anterior; Adenomatous Polyposis Coli; Aging; Amyotrophic Lateral Sclerosis; Anemia; Anemia, Aplastic; Anemia, Sickle Cell; Angiomyolipoma; Bronchitis; Carcinoma, Renal Cell; Castleman Disease; Depressive Disorder; Dry Eye Syndromes; Fanconi Anemia; Gliosarcoma; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; Graves Ophthalmopathy; Hemangioendothelioma; Hematologic Diseases; Hypertension; Immunologic Deficiency Syndromes; Intracranial Aneurysm; Intracranial Arteriovenous Malformations; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Neoplasms; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphedema; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell, Cutaneous; Macular Degeneration; Multiple Myeloma; Multiple System Atrophy; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibromatosis 1; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Pinealoma; Polycystic Kidney Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Retroperitoneal Fibrosis; Sarcoidosis; Sarcoma; Sarcoma, Ewing; Scleroderma, Systemic; Severe Acute Respiratory Syndrome; Severe Combined Immunodeficiency; Sturge-Weber Syndrome; Thyroid Neoplasms; Tuberous Sclerosis; Uveitis, Intermediate; Uveitis, Posterior; Vascular Malformations; Vitiligo; Wet Macular Degeneration; beta-Thalassemia; Birt-Hogg-Dube Syndrome; Breast Neoplasms; Carcinoma, Hepatocellular; Cardiovascular Abnormalities; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fibroma; Graft vs Host Disease; Hodgkin Disease; Lichen Planus, Oral; Lymphangioleiomyomatosis; Lymphoma, Non-Hodgkin; Myositis, Inclusion Body; Neurofibromatoses; Pachyonychia Congenita; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Skin Neoplasms; Urinary Bladder Neoplasms; Eye Diseases; Immune System Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 protease inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Acquired Immunodeficiency Syndrome; HIV Infections; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosinase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Peroxisome proliferator-activated receptor gamma agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: DIABETES DRUGS & ENDOCRINOLOGY; OTHER
THERAPEUTIC INDICATION: HIV Infections; Central Nervous System Neoplasms; Head and Neck Neoplasms; Heart Failure; Leukoplakia, Oral; Non-alcoholic Fatty Liver Disease; Pituitary ACTH Hypersecretion; Sarcoma; Atherosclerosis; Insulin Resistance; Diabetes Mellitus; Diabetes Mellitus, Type 2
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase-2 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: MUSCULOSKELETAL; OTHER; RHEUMATOLOGY
THERAPEUTIC INDICATION: Brain Neoplasms; Glioma; Alzheimer Disease; Carcinoma, Non-Small-Cell Lung; Adenoma; Colorectal Neoplasms; Joint Diseases; Osteoarthritis; Osteoarthritis, Knee; Pain; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Rheumatic Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anemia; Astrocytoma; Brain Neoplasms; Crohn Disease; Cystic Fibrosis; Diabetes Mellitus, Type 1; Glioblastoma; Granulomatous Disease, Chronic; Lupus Erythematosus, Systemic; Melanoma; Meningioma; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Prostatic Neoplasms; Pulmonary Alveolar Proteinosis; Adrenoleukodystrophy; Alcoholism; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Asthma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiovascular Diseases; Cerebral Hemorrhage; Child Development Disorders, Pervasive; Cognitive Dysfunction; Depressive Disorder, Major; Glucose Intolerance; Hepatitis; Hepatitis C; Hepatitis C, Chronic; Hypertension, Pulmonary; Infections; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liposarcoma; Liposarcoma, Myxoid; Lung Neoplasms; Non-alcoholic Fatty Liver Disease; Obesity; Opioid-Related Disorders; Pancreatic Neoplasms; Parkinson Disease; Polycystic Kidney Diseases; Polycystic Ovary Syndrome; Prostatic Neoplasms, Castration-Resistant; Psoriasis; Renal Insufficiency, Chronic; Stroke; Thyroid Neoplasms; Arthritis, Rheumatoid; Atherosclerosis; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Liver; Friedreich Ataxia; HIV-Associated Lipodystrophy Syndrome; Hypercholesterolemia; Hypertension; Liver Diseases; Metabolic Syndrome; Diabetes Mellitus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Contracture; Peanut Hypersensitivity; Conjunctivitis, Allergic; Dyspepsia; Fibromyalgia; Rhinitis, Allergic, Perennial; Severe Acute Respiratory Syndrome; Eye Manifestations; Hypersensitivity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Phosphodiesterase 3A inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: CADASIL; Fatty Liver; Osteoarthritis; Pain; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Heart Failure; Intermittent Claudication; Stroke; Atherosclerosis; Cardiovascular Diseases; Cerebral Infarction; Cerebrovascular Disorders; Coronary Disease; Peripheral Arterial Disease; Peripheral Vascular Diseases; Thrombosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vitamin D receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Adrenoleukodystrophy; Anemia, Sickle Cell; Burns; Carcinoma in Situ; Carcinoma, Intraductal, Noninfiltrating; Glioblastoma; Hyperlipidemias; Irritable Bowel Syndrome; Papilloma; Pneumonia; Primary Immunodeficiency Diseases; Sarcopenia; Skin Neoplasms; Tibial Fractures; Acquired Immunodeficiency Syndrome; Aging; Autistic Disorder; Bronchiolitis; Colonic Neoplasms; Common Cold; Conjunctivitis, Allergic; Depressive Disorder; Dermatitis, Atopic; Diabetes Mellitus; Glucose Intolerance; Hematologic Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Hypersensitivity; Infertility, Male; Keratosis, Actinic; Leukemia, Myeloid, Acute; Malnutrition; Metabolic Syndrome; Multiple Sclerosis; Neoplasms; Neurofibromatosis 1; Optic Neuritis; Ovarian Neoplasms; Parkinson Disease; Prediabetic State; Prostatic Neoplasms, Castration-Resistant; Psoriasis; Psychotic Disorders; Pulmonary Disease, Chronic Obstructive; Rectal Neoplasms; Respiratory Insufficiency; Staphylococcal Infections; Urinary Tract Infections; Adenoma; Arthritis, Juvenile; Asthma; Bone Diseases, Metabolic; Breast Neoplasms; Cardiovascular Diseases; Cognitive Dysfunction; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Epilepsy; Fractures, Bone; HIV Infections; Heart Failure; Helicobacter Infections; Hepatitis C; Hip Fractures; Hyperparathyroidism; Hypogonadism; Infections; Inflammatory Bowel Diseases; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Lipid Metabolism Disorders; Lupus Erythematosus, Systemic; Melanoma; Multiple Sclerosis, Relapsing-Remitting; Non-alcoholic Fatty Liver Disease; Obesity; Osteitis Deformans; Osteoporosis, Postmenopausal; Polycystic Ovary Syndrome; Pregnancy; Prostatic Neoplasms; Renal Insufficiency, Chronic; Schizophrenia; Severe Acute Respiratory Syndrome; Tuberculosis; Tuberculosis, Pulmonary; Urticaria; Vitamin D Deficiency; Anemia; Anemia, Iron-Deficiency; Osteoporosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Aortic Aneurysm, Abdominal; Asthma; Muscular Dystrophy, Duchenne
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anemia; Breast Neoplasms; Erectile Dysfunction; Glomerulosclerosis, Focal Segmental; Malaria; Malaria, Falciparum; Nausea; Neoplasms; Arthritis, Rheumatoid; Asthma; Cognitive Dysfunction; Colitis, Ulcerative; Endometriosis; HIV Infections; Insulin Resistance; Mycosis Fungoides; Non-alcoholic Fatty Liver Disease; Prediabetic State; Sezary Syndrome; Alzheimer Disease; Atherosclerosis; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glucose Intolerance; Hypercholesterolemia; Hypertension; Lipid Metabolism Disorders; Metabolic Diseases; Metabolic Syndrome; Multiple Organ Failure; Prostatic Neoplasms; Diabetes Mellitus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor agonist
ROUTE OF ADMINISTRATION: ORAL; VAGINAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER; PREGNANCY AND GYNECOLOGY
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asthma; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Gastric lipase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Metabolic Syndrome; Hyperlipoproteinemia Type I; Polycystic Ovary Syndrome; Infertility; Obesity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Catechol O-methyltransferase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Epilepsy; Obesity; Cocaine-Related Disorders; Parkinson Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial 70S ribosome inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Communicable Diseases; Hematologic Neoplasms; Neoplasms; Dyspepsia; Duodenal Ulcer; Gastrointestinal Hemorrhage; Helicobacter Infections; Gastroesophageal Reflux; Peptic Ulcer
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vitamin D receptor agonist
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: DIABETES DRUGS & ENDOCRINOLOGY; OTHER; UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Neoplasms; Prostatic Neoplasms, Castration-Resistant; Psoriasis; Hyperparathyroidism, Secondary; Parathyroid Diseases; Renal Insufficiency, Chronic